Increasing access with Indian generics
For more than a decade, Gilead has been working in partnership with governments, healthcare systems, providers, public health entities and generic manufacturers to make its HIV and hepatitis B medicines available worldwide. Currently, 7.6 million people living with HIV in developing countries receive Gilead antiretroviral medicines through these efforts. Gilead is now working to help ensure broad access to its hepatitis C medicines in developing countries.